Wealth Firm Picks Activist Investor Fight
Citing a fiduciary duty to its clients, financial planning firm Richmond Brothers has taken the unusual step of launching a proxy attack on Rockwell Medical, a Nasdaq-listed company that develops and markets treatments for kidney diseases.
“I’ve never heard of a firm like ours doing anything like this,” says David Richmond, board chairman and co-owner of Jackson, Mich.-based Richmond Brothers, an RIA that manages about $300 million. “But we hang our own shingle and create our own opportunities and liabilities, and we truly believe we’re doing what’s right for our clients.”
Richmond Brothers, on behalf of its executives and clients, and in partnership Mark Ravich, a Minneapolis-based businessman – who together represent almost 12% of Rockwell Medical’s outstanding common stock – wants a seat on Rockwell’s board to steer the company toward new strategies.
These shareholders want Rockwell Medical to improve sales of Triferic, an iron-replacement drug that’s done well in clinical reviews, and position itself for success with Calcitriol, a generic drug for patients in need of dialysis for which the company soon expects to receive FDA approval to manufacture.
In addition, says Richmond, the activists feel Rockwell Medical’s management – especially its CEO and founder Rob Chioini – is over-compensated.
Wixom, Mich.-based Rockwell Medical has a market capitalization of $457.5 million on 51.5 million shares and an intraday share price of $8.68 on April 27, according to Google Finance.
“This could be a $40 stock,” says Richmond, who has owned shares in Rockwell Medical since “about 2002” and started recommending the issues to clients shortly thereafter.
Chioini has told the dissident shareholders Rockwell Medical has a long-term strategy “to grow revenue by first securing the highest Medicare reimbursement possible, signing lucrative contracts with national dialysis companies for Triferic” and carving out partnerships for international sales, according to Crain’s Detroit Business.
“We have met with and tried to work with David, and for whatever reason, we are where we are today,” Chioini tells Crain’s, referring to Richmond by his first name.
Richmond says he’d rather fight than sell his Rockwell Medical shares — or recommending his clients do so — because he has the means to effect positive change at the company and he owes it to his clients to try.
“If we are not on the board they’re not going to do the right thing,” he says. “Our whole idea is to unlock the full value of the stock” as part — he says — of his firm’s fiduciary obligation to his clients.
But does Richmond Brothers run afoul of the fiduciary standard when its executive personally owns shares in the company he’s fighting?
Not at all, says Tamar Frankel, an expert on business ethics, fiduciary law and corporate governance.
“They’re saying they were entrusted with the power to represent their clients and use their expertise and judgment in doing that,” Frankel, a professor at Boston University’s law school, says of Richmond Brothers in its role as activist shareholder. “That’s what the fiduciary duty is.”
Adds Frankel: “If they judge there is no conflict — and if it’s something they themselves would do — then there is no conflict.”
That said, Frankel believes Richmond Brothers is taking a slight fiduciary risk in one respect. If the firm’s actions with respect to Rockwell Medical are born of a desire “to make a reputation” and if these actions end up harming clients — by, for instance, further reducing the value of the shares in question — it might amount to “a very thin and watery conflict” in the form of a potential reduction “in the value of their judgment.”
Richmond seems to be of two minds about that.
On one hand, he doesn’t plan to make his firm a serial — or even a repeat — shareholder activist. He thinks it’s too time-consuming and expensive. “All the costs are coming out of our pockets personally,” he says, referring to himself and other brass at Richmond Brothers. “We can’t charge clients for any of this. It’s not in our business model, so it wouldn’t be fair.”
On the other hand, Richmond sees activism as a significant value-add that could get on the menu at some RIAs.
“If you look at the industry, a lot of people are saying there will be fewer RIAs and those will be bigger than they generally are now,” Richmond tells FA-IQ. “At the same time, activism has blossomed, so it “could be part of an RIA’s service offering” — even if it calls for “a strong stomach” and a willingness “to spend a lot of money.”
In conclusion, says Richmond, “If I were a client, I would want to be with someone who was willing to walk to the ends of the earth for me.”
The spat between Rockwell Medical and the activists may come to a head on June 1. That’s when the company has its next shareholder meeting.